Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25487372 | 0.84 | KMT2A (0.41) | LMNASMN1; SMN2TSHRL3MBTL1SLC6A4 | |
| SCHEMBL29428931 | 0.84 | CA1 (0.45) | TSHRL3MBTL1TDP1HTR6KCNH2 | |
| SCHEMBL3820431 | 0.84 | CA1 (0.45) | TSHRL3MBTL1TDP1HTR6KCNH2 | |
| SCHEMBL24252065 | 0.81 | ALDH1A1 (0.41) | LMNASMN1; SMN2TSHRTDP1HPGD | |
| SCHEMBL19867161 | 0.81 | L3MBTL1 (0.40) | LMNASMN1; SMN2L3MBTL1SLC6A4SLC6A2 | |
| SCHEMBL914798 | 0.80 | LMNA (0.43) | LMNASMN1; SMN2TSHRL3MBTL1SLC6A4 | |
| SCHEMBL28003345 | 0.80 | LMNA (0.43) | LMNASMN1; SMN2TSHRL3MBTL1SLC6A4 | |
| SCHEMBL3789902 | 0.79 | L3MBTL1 (0.39) | LMNASMN1; SMN2TSHRL3MBTL1SLC6A2 | |
| SCHEMBL6305084 | 0.79 | LMNA (0.44) | LMNASMN1; SMN2TSHRL3MBTL1SLC6A4 | |
| SCHEMBL4122925 | 0.78 | KMT2A (0.43) | LMNASMN1; SMN2TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-10725377-B2 | Chemically amplified negative resist composition and resist pattern forming process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-07-28 | — | — | US | disclosed |
| EP-3343292-B1 | CHEMICALLY AMPLIFIED NEGATIVE RESIST COMPOSITION AND RESIST PATTERN FORMING PROCESS | SHINETSU CHEMICAL CO (JP) | 2020-05-06 | — | — | EP | disclosed |
| US-20190350906-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2019-11-21 | — | — | US | disclosed |
| CN-107935899-B | Sulfonium compound, anti-corrosion agent composition and pattern forming method | 信越化学工业株式会社 | 2019-11-12 | — | — | CN | disclosed |
| EP-3343291-B1 | CHEMICALLY AMPLIFIED POSITIVE RESIST COMPOSITION AND RESIST PATTERN FORMING PROCESS | SHINETSU CHEMICAL CO (JP) | 2019-08-14 | — | — | EP | disclosed |
| US-10173975-B2 | Sulfonium compound, resist composition, and pattern forming process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| US-10035790-B2 | RORγ modulators | EXELIXIS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20080021070-A1 | PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2008-01-24 | — | — | US | disclosed |
| US-20080021070-A1 | PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2008-01-24 | — | — | US | disclosed |
| US-7288537-B2 | Azetidine derivatives as CCR-3 receptor antagonists | NOVARTIS AG (CH) | 2007-10-30 | — | — | US | disclosed |
| US-7288537-B2 | Azetidine derivatives as CCR-3 receptor antagonists | NOVARTIS AG (CH) | 2007-10-30 | — | — | US | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20070129372-A1 | P38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. | 2007-06-07 | — | — | US | disclosed |
| CN-1915949-A | Technical method for synthesizing beta p-hydroxy phenethyl alcohol | SHENYANG TECH UNIV (CN) | 2007-02-21 | — | — | CN | disclosed |
| US-20060224011-A1 | Catalyst composition and process for producing cross-coupled compound using same | TOSOH CORPORATION | 2006-10-05 | — | — | US | disclosed |
| EP-1707263-A1 | Catalyst composition comprising an alkylene diamine-nickel complex and process for producing a cross-coupled compound using the same | Tosoh Corporation (JP) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | LMNA 2098/4885SMN1; SMN2 2486/4885TSHR 4257/4885 |
| US-20080021070-A1 | PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | CNR1, CNR2, GPR18 | LMNA 2315/4885SMN1; SMN2 4195/4885TSHR 477/4885 |
| US-10035790-B2 | RORγ modulators | RORB, RORA, RORC | LMNA 2906/4885SMN1; SMN2 3896/4885TSHR 220/4885 |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | CNR1, CNR2, OPRD1 | LMNA 4698/4885SMN1; SMN2 4282/4885TSHR 436/4885 |
| US-10173975-B2 | Sulfonium compound, resist composition, and pattern forming process | C1R, LBR, SMARCC2 | LMNA 690/4885SMN1; SMN2 1489/4885TSHR 2314/4885 |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | LMNA 2098/4885SMN1; SMN2 2486/4885TSHR 4257/4885 |
| US-10725377-B2 | Chemically amplified negative resist composition and resist pattern forming process | SLC11A2, POLR2B, POLI | LMNA 1360/4885SMN1; SMN2 1675/4885TSHR 4408/4885 |
| US-20060224011-A1 | Catalyst composition and process for producing cross-coupled compound using same | C5, TST, PYM1 | LMNA 4553/4885SMN1; SMN2 3889/4885TSHR 87/4885 |
| US-20190350906-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | LMNA 2098/4885SMN1; SMN2 2486/4885TSHR 4257/4885 |
| US-20070129372-A1 | P38 kinase inhibiting agents | MAPK1, MAPK8, MAPK7 | LMNA 4285/4885SMN1; SMN2 4239/4885TSHR 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.